Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- 16 APIs Including Aricept, Lyrica to Be Re-Priced for Market Expansion
January 25, 2012
- MHLW to Issue Revised Notifications in Preparation for Application to PIC/S
January 25, 2012
- Revised Basic Plan Against Cancer to Include Pediatric Cancer Measures
January 24, 2012
- Senior Vice Minister Tsuji to Actively Support Creation of 3rd-Party Organization
January 23, 2012
- Proposed Amendment of PAL Would Require Submission of Package Inserts: Mr Kikura
January 23, 2012
- Huge Drop in Compliance Rate for “Explanations in Writing” in Sales of Class 1 OTC Drugs: MHLW Undercover Survey
January 20, 2012
- PMDA to Introduce Direct ADR Reporting System for Patients on Trial Basis
January 20, 2012
- Prof. Nakamura of Keio Univ. Sees Orphan Drug Development Strategy as Reason for Revised Re-pricing Policy
January 20, 2012
- EMA Initiates Review of Oral MS Treatment Gilenya Following Reports of Heart Problems
January 20, 2012
- PAFSC’s Second Committee on Drugs to Review Kyowa Kirin’s ATL Treatment on February 1
January 19, 2012
- PMDA to Expand PGx, Biomarker Consultation System
January 19, 2012
- MHLW Considering “Partial Introduction” of Medico-Economic Evaluation in FY2014
January 18, 2012
- No Serious Concerns Observed for 4 Vaccines: MHLW Study Groups
January 17, 2012
- US Industry Opinion Divided on Japan’s Participation in TPP Talks
January 17, 2012
- PAFSC’s First Committee on Drugs to Review Zyprexa for Depression in Bipolar Disorder on January 27
January 16, 2012
- MHLW Proposes New Fee for Medical Management of Treatment-Resistant Schizophrenia
January 16, 2012
- MHLW Director Tawaragi Raises 3 Points, Including Risk Management Planning, as Priority Measures for FY2012
January 13, 2012
- MHLW to Strengthen Support for Ultra-Orphan Drug Development
January 13, 2012
- PFSB Calls for Revision of Package Inserts for 15 Products
January 12, 2012
- MHLW Revises Ministerial Ordinance to Prohibit Dispensing Point Services by Pharmacies
January 12, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…